Please login to the form below

Not currently logged in
Email:
Password:

Gene editing

This page shows the latest Gene editing news and features for those working in and with pharma, biotech and healthcare.

ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more

ASH 2020: Gilead eyes new Yescarta indication, Vertex/CRISPR make headway in sickle cell and more

Vertex/CRISPR Therapeutics make headway in sickle cell and beta thalassaemia. Also presenting data at ASH were Vertex and CRISPR Therapeutics, whose gene-editing therapy CTX001 scored some promising results in ... bluebird bio’s beta thalassaemia gene

Latest news

More from news
Approximately 6 fully matching, plus 52 partially matching documents found.

Latest Intelligence

  • Alzheimer’s: the search for a cure Alzheimer’s: the search for a cure

    gene-editing specialist Sangamo for rights to tau-targeting drug ST-501 as part of a broader R&D alliance. ... Such a shift has recently happened in the gene therapy space, which was a backwater pursued largely by biotech until the progress of companies

  • Novo Nordisk awakens its ‘Sleeping Beauty’ Novo Nordisk awakens its ‘Sleeping Beauty’

    The next phases were to enrich the pipeline with acquisitions and partnerships, including a headline deal with blue-bird bio for next generation gene editing that could lead to a potential ... We also have a stem cell platform, gene editing, an exquisite

  • It started with a miss It started with a miss

    There are huge implications for communications. Take gene editing, for example. ... We’re going to get to the point where treatments like gene therapies will be ubiquitous – so we need to set ourselves up for them now and embrace the ethical debate

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    Europe is the test ground for the gene therapy pioneer’s outcomes-based model, which could set the standard for the emerging sector. ... These include pipeline gene-editing therapies from Sanofi and luspatercept from Celgene to name but a few, although

  • Vertex: a vision of treating all CF patients worldwide draws closer Vertex: a vision of treating all CF patients worldwide draws closer

    A gene therapy cure for all the world’s CF patients would be a truly remarkable achievement. ... These include alpha-1 antitrypsin deficiency and focal segmental glomerulosclerosis. It’s also working with CRISPR Therapeutics on phase 1/2 clinical

More from intelligence
Approximately 2 fully matching, plus 14 partially matching documents found.

Latest appointments

  • Eric Rhodes becomes CEO of ERS Genomics Eric Rhodes becomes CEO of ERS Genomics

    In these roles, Rhodes was responsible for commercialising the company's genome editing technologies as well as driving its research and development. ... Biosciences. Foy said: “With his deep understanding of the gene-editing landscape and extensive

  • Marc Becker joins CRISPR Therapeutics Marc Becker joins CRISPR Therapeutics

    He becomes chief financial officer. CRISPR Therapeutics has appointed Marc Becker as its new chief financial officer with remit to drive development of its gene-editing technology platform.

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

  • Spotlight interview: 15 minutes on medical and scientific writing

    A number of current therapeutic approaches – such as gene editing, gene therapy, and stem-cell therapy – were not in existence when many healthcare professionals (HCPs) underwent their training, so there is

  • 'Fake news': battling misinformation in healthcare

    After reading this headline, it’s easy to assume that some form of gene editing has led to a cure for HIV. ... Should you read on, you would also discover that gene-editing was in no way used in this treatment.

  • Random42 Partner with MedCity for BioJapan 2018

    J. Leading UK health scientists, universities and national research institutions will provide insight into the UK life sciences sector, and their work in ageing, gene editing and artificial intelligence.

  • Training the next generation of biotech leaders

    Novel technologies, coupled with programmes designed to drive cell and gene research and development, are ushering in a new era of therapies. ... It’s such a disruptive advancement – it’s just incredible to think it has all been made feasible

  • Perspective on biotech

    The emerging technologies revolutionising the biotech industry – from immunotherapy breakthroughs to cutting-edge gene editing techniques.

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

2020 - a year to remember or forget?
2020 and the Covid pandemic brought immense challenges, and the need for change felt like it happened overnight. What have we learned and what does the future of agency working...
Gilead Headquarters
The search for effective drug treatments for COVID-19
PME talks to Julian Cole, Senior Director, Medical Affairs at Gilead Sciences...
PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...

Infographics